InsiderTrades.com logo

ARDX Insider Trading

Insider Ownership Percentage: 5.90%
Insider Buying (Last 12 Months): $2,377,766.00
Insider Selling (Last 12 Months): $7,304,486.72

Ardelyx Insider Trading History Chart

This chart shows the insider buying and selling history at Ardelyx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Ardelyx Share Price & Price History

Current Price: $4.74
Price Change: ▼ Price Decrease of -0.14 (-2.87%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for ARDX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$4.88Closing price on 04/02/25:

SEC Filings (Institutional Ownership Changes) for Ardelyx (NASDAQ:ARDX)

58.92% of Ardelyx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARDX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$96Mbought$18MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
Ardelyx logo
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Read More on Ardelyx

Today's Range

Now: $4.74
Low: $4.53
High: $4.83

50 Day Range

MA: $5.38
Low: $4.74
High: $6.42

52 Week Range

Now: $4.74
Low: $4.32
High: $9.33

Volume

6,585,792 shs

Average Volume

4,355,029 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

Who are the company insiders with the largest holdings of Ardelyx?

Ardelyx's top insider investors include:
  1. David M Mott (Director)
  2. Michael Raab (CEO)
  3. David P Rosenbaum (Insider)
  4. Laura A Williams (Insider)
  5. Robert Blanks (Insider)
  6. Susan Rodriguez (Insider)
  7. Justin A Renz (CFO)
  8. Elizabeth A Grammer (Insider)
  9. Robert Ora Felsch (Insider)
Learn More about top insider investors at Ardelyx.